Skip to main content

Month: June 2020

Kelso Technologies Inc. Announces Annual General and Special Meeting Results

VANCOUVER, British Columbia and BONHAM, Texas, June 25, 2020 (GLOBE NEWSWIRE) — Kelso Technologies Inc. (“Kelso” or the “Company”), (TSX: KLS), (NYSE American: KIQ) is pleased to announce the detailed voting results from the Annual General and Special Meeting held earlier today (the “Meeting”).A total of 22,845,167 common shares of the 47,170,086 common shares outstanding at the record date were voted at the Meeting, representing 49.03% of the issued and outstanding common shares of the Company at the record date.Election of DirectorsEach of the following nominees set forth in the Company’s management proxy circular dated May 19, 2020 was elected as a director of the Company to hold office until the next annual meeting of shareholders or until their successors are elected or appointed:At the Meeting the shareholders also approved...

Continue reading

Epoxy Technology, Inc. Announces New Logo

BILLERICA, Massachusetts, June 25, 2020 (GLOBE NEWSWIRE) — Epoxy Technology, Inc., (ETI) a leader in the development and manufacture of specialty epoxy, UV & UV hybrid adhesives, revealed the company’s new logo today. This change in ETI’s visual identity coincides with the company’s focus on increasing its global presence in the market, as well as the company’s renewed commitment to its reputation as a trusted solution provider to its partners. Established in 1966, ETI has built a solid foundation on its agile customer service, advanced technology and innovative products. ETI was purchased in 2018 by Meridian Adhesives Group (Meridian), a leading platform in the global adhesives sector. Becoming part of the Meridian portfolio, ETI is better positioned to meet the needs of customers through Meridian’s advanced technological platform....

Continue reading

Novartis Resolves Legacy FCPA Investigations

Basel, June 25, 2020 – Novartis has reached settlements with the US Department of Justice (DOJ) and the US Securities and Exchange Commission (SEC) resolving all Foreign Corrupt Practices Act (FCPA) investigations into historical conduct by the Company and its subsidiaries. As part of the settlements, Novartis and certain of its current and former subsidiaries will pay USD 233.9 million to the DOJ and USD 112.8 million to the SEC.To resolve the DOJ investigation, Novartis Hellas S.A.C.I. has entered into a deferred prosecution agreement (“Novartis Hellas DPA”) pertaining to inappropriate economic benefits provided to Greek healthcare professionals from 2012 to 2015 in connection with the ophthalmology product Lucentis. The Novartis Hellas DPA also covers books and records issues pertaining to the Lucentis conduct and to conduct related...

Continue reading

Aéroports de Paris SA: €1.5 billion dual-tranche new bond issue

FINANCIAL RELEASE25 June 2020Aéroports de Paris SA€1.5 billion dual-tranche new bond issueOn 25 June 2020, Aéroports de Paris launched a dual-tranche bond issue for a total amount of €1.5 billion with the following characteristics:€750 million bond :Format: Fixed rate  Redemption: in fine  Duration: 8.5 yearsAnnual rate: 1.00%Re-offer spread: 150 bp over mid swapRe-offer yield: 1.266%Payment date: 2 July 2020Maturity date: 5 January 2029 €750 million bond :Format: Fixed rate Redemption: in fine Duration: 12 yearsAnnual rate: 1.50%Re-offer spread: 175 bp over mid swapRe-offer yield: 1.649%Payment date: 2 July 2020Maturity date: 2 July 2032Aéroports de Paris is rated A (negative outlook) by Standard and Poor’s.Investor Relations: Audrey Arnoux, Head of Investor Relations +33 6 61 27 07 39 – invest@adp.frPress contact: Lola Bourget,...

Continue reading

Aéroports de Paris SA : Emission d’un nouvel emprunt obligataire de 1,5 milliard d’euros en deux tranches

COMMUNIQUE FINANCIERTremblay-en-France, le 25 juin 2020Aéroports de Paris SAEmission d’un emprunt obligataire en deux tranchespour un montant total de 1,5 milliard d’eurosLe 25 juin 2020, Aéroports de Paris a lancé le placement d’un emprunt obligataire en 2 tranches d’un montant total de 1,5 milliard d’euros ayant les caractéristiques suivantes :Emprunt de 750 millions d’euros :Format : Taux fixeRemboursement : in fine        Durée : 8,5 ansTaux annuel : 1,00 %Marge au re-offer : 150 bps au-dessus du mid swapTaux re-offer : 1,266 %Date de règlement : 2 juillet 2020Date d’échéance finale : 5 janvier 2029Emprunt de 750 millions d’euros :Format : Taux fixeRemboursement : in fine        Durée : 12 ansTaux annuel : 1,50 %Marge au re-offer : 175 bp au-dessus du mid swapTaux re-offer : 1,649 %Date...

Continue reading

Beamz Interactive Announces Inclusion of Additional Content and a Major Sale With Its Jam Studio VR Apps

SAN FRANCISCO, June 25, 2020 (GLOBE NEWSWIRE) — Beamz Interactive, Inc. (OTCMKTS: BZIC), a leading developer of state-of-the-art interactive AI music technology and products, today announced Expanded Content and a 50% OFF SALE on Steam with Jam Studio VR, a fun, family-oriented interactive music experience that enables individuals of all ages and abilities – with no musical training – to play realistic virtual musical instruments and perform extraordinary DJ and Interactive Music in VR, while simultaneously receiving a wide variety of learning, cognitive, social/emotional, communicative, physical, sensory and therapy benefits. This new content includes additional realistic instrument choices in certain songs, Golden Oldie songs “New York, New York” and “Old Time Rock and Roll” in the style of...

Continue reading

NeuroMetrix Signs DPNCheck® Collaboration Agreement with Biomedix

WOBURN, Mass., June 25, 2020 (GLOBE NEWSWIRE) — NeuroMetrix, Inc. (Nasdaq: NURO) today reported that it has signed a collaboration agreement with Biomedix to comarket DPNCheck for peripheral neuropathy detection within Medicare Advantage and other value-based care markets. NeuroMetrix and Biomedix provide complementary diagnostic tests to physicians and health plans. Within these markets, healthcare providers are focused on detecting and documenting chronic health conditions to determine risk and prevent their costly and debilitating complications.Biomedix will integrate DPNCheck sural nerve conduction data into the Biomedix Xchange population health platform. This will simplify the documentation process for health plans by combining results from multiple diagnostic tests into one data exchange file for the electronic medical record...

Continue reading

GBT Awards $250,000 in ACCEL Grants to Advance Access to Care for People Living with Sickle Cell Disease

SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) — Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that five U.S. nonprofit organizations serving the sickle cell disease (SCD) community have been awarded a total of $250,000 through the company’s 2020 Access to Excellent Care for Sickle Cell Patients (ACCEL) Grant Program. For the second year, the ACCEL program has funded innovative programs that have the potential to deliver high-quality healthcare to people living with SCD.“Individuals living with sickle cell disease face significant challenges every day, including accessing quality healthcare in their communities. These challenges are greater than ever given the impact of COVID-19 and the healthcare disparities the pandemic has brought harshly to light,” said Jung E. Choi, chief business and strategy...

Continue reading

Encres DUBUIT : ASSEMBLEE GENERALE MIXTE DU 25 JUIN 2020

COMMUNIQUELe 25 Juin 2020Assemblée générale mixte du 25 juin 2020 à huis closL’Assemblée Générale Mixte d’Encres DUBUIT s’est tenue à huis clos le jeudi 25 juin 2020 à 14 heures 30.Toutes les résolutions ont été adoptées.Le bureau était composé comme suit :Monsieur Jean-Louis DUBUIT, président de séanceMadame Chrystelle FERRARI et Monsieur Pascal QUIRY scrutateurs de séance,Madame Julie PECQUEUX secrétaire.À propos d’Encres DUBUITCoté sur Euronext Growth Paris depuis le 11 décembre 2017 (code ISIN : FR0004030708, ALDUB), Encres DUBUIT s’impose comme le spécialiste des encres de haute-technologie. S’appuyant sur des applications multiples allant des nouvelles technologies au marquage industriel, Encres DUBUIT s’adresse à une clientèle de grands comptes internationaux dans des secteurs aussi variés que la cosmétique, l’automobile ou la...

Continue reading

REXEL ANNUAL SHAREHOLDERS’ MEETING OF JUNE 25th, 2020

REXEL ANNUAL SHAREHOLDERS’ MEETING OF JUNE 25th, 2020The combined Shareholders’ Meeting of Rexel was held today in camera at the Registered Office, under the Chairmanship of François Henrot, Vice-Chairman of the Board of Directors, in accordance with the derogatory measures adapting the rules for meetings and deliberations of shareholders’ meetings adopted by the French authorities due to the Covid-19 pandemic.The shareholders approved all the resolutions. The results of the votes and the video webcast are available on the Company’s website:https://www.rexel.com/en/medias/events/2020-annual-general-shareholders-meeting/Compensation of the Chairman of the Board of Directors, the Directors and the Chief Executive Officer:Ratification of the co-option of a Director and renewal of the term of office of three Directors:Composition...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.